Episcleral Brachytherapy for the Treatment of Wet AMD

Subjects will receive a single brachytherapy treatment and 52-weeks of follow-up.

Inclusion Criteria:

- Diagnosis of CNV or PCV due to nAMD by angiography

- Male or female aged 50 years or older

- Documentation of prior treatment for nAMD

- Patients must have demonstrated clinical or OCT/angiographic evidence that, in the
investigator's opinion, requires treatment with anti-VEGF therapy.

- BCVA 20/40 - 20/200 Snellen equivalent in study eye

- Actively leaking neovascular complex as determined by angiography

- Ability to understand nature/purpose of trial and to provide informed consent

- Ability to undergo diagnostic tests and surgical interventions

- Ability to follow instructions and complete the trial including all scheduled visits
and follow-up

Exclusion Criteria:

- Women who are pregnant or plan to become pregnant during the study

- CNV other than due to nAMD

- Sub-foveal lesion hemorrhage obscuring >50% of lesion

- CNV lesion with greatest linear dimension >3750 microns as determined by angiography

- Presence of subretinal fibrosis or retinal pigment epithelial atrophy involving the
central macula in the study eye

- Existing Retinal Pigment Epithelial tear

- Previous treatment (excluding vitamins) for nAMD in the study eye other than anti-VEGF
therapy in the last 6 months

- A change in anti-VEGF agent in the previous two administrations

- Anticipate a change to the anti-VEGF agent during the conduct of the study

- Previous intraocular surgery in study eye other than for uncomplicated
phacoemulsification cataract extraction

- Other clinically significant ocular co-morbidity including, but not limited to, optic
glaucoma, optic neuropathy of any cause, maculopathy / retinopathy of any cause other
than nAMD, and scleritis

- History of refractive error of - 6D or greater (spherical equivalent) or demonstrated
myopic degeneration

- Media opacity sufficient to preclude adequate fundoscopy, OCT or angiography

- Uncontrolled systemic diseases (e.g. controlled hypertension is acceptable)

- Type I or type II diabetes mellitus

- Clinically significant previous radiation to the eye

- On anticoagulation or dual anti-platelet therapy with abnormal coagulation panel
results.

- Patient unsuitable for IV or local anesthesia

- Any contraindication to anti-VEGF, fluorescein, topical and local anesthetics, topical
antiseptics, or topical antibiotics to be used during the study

- Active ocular or periocular infection or intraocular inflammation

- Fellow eye with worse visual acuity than the study eye.

- Any condition which, in the investigators' opinion, would conflict or otherwise
prevent the subject from complying with the required procedures, schedule or other
study conduct